Announcement on Meiasartan Potassium Tablets Obtaining Drug Registration Certificate

Rundu Co., Ltd.·July 12, 2026·2 pages

✨ AI Summary

Zhuhai Rundu Pharmaceutical Co., Ltd. announced it has received two Drug Registration Certificates from the NMPA for Meiasartan Potassium Tablets. This approval, following the earlier raw material approval, completes the vertical integration of the product chain and enhances market competitiveness. The company anticipates this will further its product layout in cardiovascular and cerebrovascular treatments.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Stock Code: 002923

Stock Abbreviation: Rundu Shares

Announcement Number: 2026-049

Zhuhai Rundu Pharmaceutical Co., Ltd.

Announcement on Meiasartan Potassium Tablets Obtaining Drug Registration Certificate

The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and are free from false records, misleading statements, or major omissions.

Zhuhai Rundu Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") recently received two "Drug Registration Certificates" for Meiasartan Potassium Tablets issued by the National Medical Products Administration. The relevant situation is hereby announced as follows:

I. Basic Information of the Drug

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.